Fig. 6 | Scientific Reports

Fig. 6

From: LEM4 interacts with β-catenin and promotes β-catenin-dependent transcription activity to confers ribociclib resistance in breast cancer cells

Fig. 6

Reversal of ribociclib resistance by inhibiting β-catenin activity. (A) Significant reduction of β-catenin activity in the nuclear fractions of both parental and drug-resistant cells upon treatment with a β-catenin activity inhibitor (XAV-939). (B) Suppression of β-catenin target gene expression after treatment with XAV-939. (C) LDH assay showing enhanced ribociclib toxicity (0.2 µM ribociclib, 48 h) in parental cells and sensitization of drug-resistant cells to ribociclib treatment upon inhibition of β-catenin activity. (D) Flow cytometry analysis confirming increased apoptosis with ribociclib treatment (0.2 µM ribociclib, 48 h) after β-catenin inhibition. Data are summary of 3 independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

Back to article page